Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

[Pain management by molecular target drugs].

Nakagawa T.

Nihon Rinsho. 2012 Nov;70 Suppl 8:388-92. Japanese. No abstract available.

PMID:
23513871
2.

Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease.

Tilg H, Vogel W, Wiedermann CJ, Shapiro L, Herold M, Judmaier G, Dinarello CA.

Hepatology. 1993 Nov;18(5):1132-8.

PMID:
8225219
3.

Inhibitory effects of whole and parotid saliva on immunomodulators.

Wozniak KL, Arribas A, Leigh JE, Fidel PL Jr.

Oral Microbiol Immunol. 2002 Apr;17(2):100-7.

PMID:
11929557
5.

Targets for sepsis therapies: tumor necrosis factor versus interleukin-1.

Russell DA, Thompson RC.

Curr Opin Biotechnol. 1993 Dec;4(6):714-21. Review.

PMID:
7764470
6.

Dexamethasone inhibits IL-1 and TNF activity in human lung fibroblasts without affecting IL-1 or TNF receptors.

Monick MM, Aksamit TR, Geist LJ, Hunninghake GW.

Am J Physiol. 1994 Jul;267(1 Pt 1):L33-8.

PMID:
7519403
7.
8.

The evolution and progression of complex regional pain syndrome (CRPS): recent insights into the nociceptive role of cytokines and management of CRPS with anticytokine therapy.

Kapoor S.

Curr Sports Med Rep. 2010 May-Jun;9(3):183; author reply 183. doi: 10.1249/JSR.0b013e3181de0d97. No abstract available.

PMID:
20463504
9.

Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.

Eibl JK, Strasser BC, Ross GM.

Neurochem Int. 2012 Dec;61(8):1266-75. doi: 10.1016/j.neuint.2012.10.008. Epub 2012 Oct 26. Review.

PMID:
23103525
10.

Regulation of lipopolysaccharide sensitivity by IFN regulatory factor-2.

Cuesta N, Salkowski CA, Thomas KE, Vogel SN.

J Immunol. 2003 Jun 1;170(11):5739-47.

11.

[Molecular mechanisms of chronic pain and its therapeutic strategy].

Takazawa T, Saito S.

Masui. 2013 Mar;62(3):275-82. Japanese.

PMID:
23544328
12.

Biologics in the treatment of chronic pain: a new era of therapy?

Bannwarth B, Kostine M.

Clin Pharmacol Ther. 2015 Feb;97(2):122-4. doi: 10.1002/cpt.20. Epub 2014 Dec 15.

PMID:
25670514
13.

Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases.

Dinarello CA.

Semin Immunol. 1992 Jun;4(3):133-45. Review.

PMID:
1320950
14.

[The role of TNF-alpha as pain mediator].

Schaible HG.

Z Rheumatol. 2010 May;69(3):237-9. doi: 10.1007/s00393-010-0619-z. Review. German.

PMID:
20309696
15.

Pain--unmet need and emerging targets & therapies.

Pillarisetti S.

CNS Neurol Disord Drug Targets. 2011 Aug;10(5):527-8. No abstract available.

PMID:
21631406
16.

Should we consider tumor necrosis factor as the only target in spondyloarthritides?

Ferraccioli G, Gremese E.

J Rheumatol Suppl. 2012 Jul;89:94-6. doi: 10.3899/jrheum.120255. Review.

PMID:
22751604
17.
18.

The role of cytokines in the pathophysiology of chronic liver diseases.

Tilg H.

Int J Clin Lab Res. 1993;23(4):179-85. Review.

PMID:
8123873
19.
20.

[Molecular target therapy for myelodysplastic syndrome].

Morita Y, Tanaka H, Matsumura I.

Nihon Rinsho. 2012 Nov;70 Suppl 8:508-12. Japanese. No abstract available.

PMID:
23513892

Supplemental Content

Support Center